Latest Content

Six years after a B-cell ALL diagnosis at 21, William Yank shares how his view of therapy changed and why he is still working on his mental health.

A Phoenix man with metastatic castration-sensitive prostate cancer shares how back pain led to a PSA test and how his family helped him cope.

Five CURE bloggers living with breast cancer share what Breast Cancer Awareness Month can miss, from metastatic disease to men and mammogram limits.

A study of 39,184 people with solid tumors, published Oct. 8, 2026, found that about 1 in 6 had an inherited genetic change that increased their cancer risk. Testing only people under 50 would have missed 72% of those with these changes.

Updated NCCN guidelines for mantle cell lymphoma favor BTK inhibitor pills in first treatment and say people with no detectable lymphoma after treatment can skip a stem cell transplant.

From a personalized melanoma vaccine to new options for biliary, stomach, lung and endometrial cancers, here are 5 ESMO 2026 abstracts to watch.

In the phase 2 CO.28 trial, all 4 patients with tumor DNA in their blood after chemotherapy were recommended surgery, versus 38.1% of those without it.

California Gov. Gavin Newsom signed AB 1682 on Sept. 27, requiring large-group health plans to cover prescribed scalp cooling starting Jan. 1, 2027. Medi-Cal coverage is pending federal approval.

In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes.

In the phase 3 ASAC trial, daily aspirin did not lower the risk of colorectal cancer returning after treatment for liver metastases, and serious side effects were more common.

Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.

Challenge yourself after cancer by building healthier habits, strengthening relationships, managing stress and embracing new experiences for a healthier life.

Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.